<DOC>
	<DOCNO>NCT01370902</DOCNO>
	<brief_summary>This trial conduct Europe . The aim dose-escalating trial ass safety , tolerability , pharmacokinetics ( rate body eliminate trial drug ) pharmacodynamics ( effect investigate drug body ) single repeat dos NNC141-0100 subject Rheumatoid Arthritis .</brief_summary>
	<brief_title>Safety Tolerability NNC0141-0000-0100 Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<criteria>A diagnosis rheumatoid arthritis ( RA ) accord American College Rheumatology ( ACR1987 classification ) least 3 month duration prior randomisation Active Rheumatoid Arthritis ( RA ) characterise DAS28CRP ( Disease Activity Score 28 joint , calculate CRP ( Creactive protein ) value ) great equal 3.2 Females must postmenopausal surgically sterile ( postmenopausal least 1 year ) willing use highly effective method birth control Males must willing use highly effective contraception Subjects stable dos methotrexate ( 7.5 25 mg/week , inclusive ) least 4 week prior randomisation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>